Improving the cost-effectiveness equation of cascade testing for familial hypercholesterolaemia.

Authors:
Pears R; Griffin M; Futema M; Humphries SE.

Journal:
Curr Opin Lipidol

Publication Year: 2015

DOI:
10.1097/MOL.0000000000000173

PMCID:
PMC4791315

PMID:
25887683

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Curr Opin Lipidol

Abbreviation: Curr Opin Lipidol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Biochemistry

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Angiopoietin-like 3 inhibition and the liver: less is more?
Oostveen RF; Hovingh GK; Stroes ESG. (2023) - Transparency Score: 3/6
Genetic variation in apolipoprotein A-V in hypertriglyceridemia.
Perera SD; Hegele RA. (2023) - Transparency Score: 3/6
The pathophysiology of excess plasma-free cholesterol.
Gillard BK; Rosales C; Gotto AM and 1 more (2023) - Transparency Score: 3/6
Characteristics of plaque lipid-associated macrophages and their possible roles in the pathogenesis…
Kim K; Park SE; Park JS and 1 more (2022) - Transparency Score: 3/6
Considerations for routinely testing for high lipoprotein(a).
Nurmohamed NS; Moriarty PM; Stroes ES. (2022) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
2/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflicts of interest There are no conflicts of interest."

Evidence found in paper:

"Financial support and sponsorship S.E.H. holds a Chair funded by the British Heart Foundation, and S.E.H. and M.F. are supported by the National Institute for Health Research University College London and Hospitals Biomedical Research Centre and by the BHF (PG08/008)."

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025